Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer
- 1 March 2002
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (5) , 1344-1352
- https://doi.org/10.1200/jco.20.5.1344
Abstract
No abstract availableThis publication has 0 references indexed in Scilit: